CompanionDx, RegenWell Sign Deal to Bring Genomics Testing to POC | GenomeWeb

NEW YORK (GenomeWeb) – CompanionDx Reference Lab announced a deal on Monday with RegenWell Holdings to bring CompanionDx's tests to the point-of-care setting.

The deal will provide RegenWell, a Georgia-based, integrated healthcare provider, access to CompanionDx's pharmacogenomics, cancer companion diagnostics, targeted next-generation sequencing, and epigenomics testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.